Picture of virus under microscope

Research under the microscope...

The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs.

Strathprints serves world leading Open Access research by the University of Strathclyde, including research by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), where research centres such as the Industrial Biotechnology Innovation Centre (IBioIC), the Cancer Research UK Formulation Unit, SeaBioTech and the Centre for Biophotonics are based.

Explore SIPBS research

Inhibition of glutathione reductase by chromium (VI)

Bibi, S. and Angeli, F. and Grant, M.H. (2004) Inhibition of glutathione reductase by chromium (VI). In: Proceedings of the British Pharmacological Society Conference 2004. British Pharmacological Society.

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

Chromium (VI) compounds have serious toxic and carcinogenic effects in humans. To exert toxicity and carcinogenicity Cr (VI) must be reduced inside cells, and it can be reduced both enzymatically and non-enyzmatically. Glutathione reductase (GR) has been implicated in the intracellular reduction of Cr (VI). This enzyme normally re-cycles reduced glutathione (GSH) from oxidized glutathione (GSSG), and is essential for protecting cells against intermediates which deplete GSH, and against oxidative stress. During its reduction inside cells Cr (VI) disrupts redox balance, and generates reactive oxygen species. These oxidize GSH and deplete reduced thiols, leading to toxicity and carcinogenesis. Susceptibility to Cr (VI) will depend on the ability of cells to protect themselves by recycling GSH via GR. The effect of exposure to Cr (VI) in vitro on the activity of GR in cells derived from liver (Hep G2 cells), colon (HT 115 cells), larynx (Hep 2 cells) and macrophages (J774.1 cells) was investigated.